Semaglutide vs Tirzepatide vs Retatrutide — GLP-1 Comparison
Three generations of GLP-1 metabolic peptides — each adding another receptor to the mix. Semaglutide targets one receptor, Tirzepatide two, and Retatrutide three. Each generation has shown greater average weight loss than the last. Here's how they compare based on clinical trial data.
Why three receptors?
The “generation” framing isn't just marketing — each receptor adds a different metabolic mechanism.
GLP-1 (all three drugs target this) — Reduces appetite, slows gastric emptying, stimulates insulin release. This is the foundation of weight loss.
GIP (added in tirzepatide and retatrutide) — Improves insulin sensitivity, modulates fat storage, may reduce nausea side effects compared to GLP-1 alone.
Glucagon (added only in retatrutide) — Increases energy expenditure and burns liver fat directly. This is why retatrutide shows up to 86% liver fat reduction in trials.
More receptors means more mechanisms working in parallel — but also more unknowns about long-term effects.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Generation | 1st | 2nd | 3rd — investigational (still in clinical trials, not yet approved for sale) |
| Receptors Targeted | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Nickname | GLP-1 agonist | Dual agonist | Triple agonist (sometimes called “Triple G” for the three receptors it targets) |
| Brand Names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | None yet — not FDA approved |
| FDA Status | Approved (diabetes 2017, obesity 2021) | Approved (diabetes 2022, obesity 2023) | Phase 3 trials (TRIUMPH program) — approval expected 2027–2028 |
| Average Weight Loss | ~14.9% over 68 weeks (STEP 1 trial) | ~22.5% over 72 weeks (SURMOUNT-1) | ~24.2% at 12mg dose (Phase 2/3 data) |
| Blood Sugar Control | Reduces HbA1c (a 3-month blood sugar marker) ~1–2% | Reduces HbA1c ~2–2.5% | Early data shows superior glucose control |
| Liver Fat Reduction | Moderate | Significant | Up to 86% reduction (Phase 3 TRIUMPH-4 data) |
| GI Side Effects | Nausea, vomiting, diarrhea — common | Similar — possibly slightly more at high doses | Similar profile — still being characterized |
| Dosing | Once weekly injection (or daily oral) | Once weekly injection | Once weekly injection (expected) |
| Availability | Widely available globally | Widely available globally | Clinical trials only — not commercially available |
| Key Trial | STEP 1 (NEJM 2021) | SURMOUNT-1, SURPASS-2 | TRIUMPH program Phase 3 |
Which one is right for you?
This is general framing for educational purposes — the actual decision should involve your prescribing physician. Insurance coverage, BMI thresholds, and individual health history all matter.
First-time considering GLP-1 therapy
Semaglutide is the most-studied option with the longest safety record (FDA-approved 2017 for diabetes, 2021 for obesity). It's the natural starting point for most patients new to this class. Available as Ozempic (diabetes), Wegovy (obesity), or Rybelsus (oral form).
Already taking semaglutide, want stronger results
Tirzepatide has now beaten semaglutide head-to-head in the SURMOUNT-5 trial — about 22.5% weight loss vs 14.9%. The dual GLP-1/GIP mechanism produces more weight loss with similar tolerability. Most patients who plateau on semaglutide find tirzepatide makes meaningful additional progress.
Have type 2 diabetes plus obesity
All three address both conditions, but tirzepatide currently has the strongest combined profile — FDA-approved for both diabetes (Mounjaro) and obesity (Zepbound), with HbA1c reduction of 2–2.5% and weight loss approaching 22.5%. Semaglutide is also dual-approved and may be preferred where insurance favors Ozempic/Wegovy coverage.
Want maximum weight loss, willing to wait
Retatrutide shows the most dramatic results in trials — about 24.2% weight loss at 12mg dose plus up to 86% liver fat reduction — but is not yet FDA-approved. Phase 3 TRIUMPH trials are running through 2026–2027, with approval expected in 2027 or 2028. Until then, retatrutide is only available through clinical trials.
Bottom Line
Each generation shows greater efficacy than the last — but more receptors means more unknowns. Semaglutide has the longest safety record and broadest availability. Tirzepatide has now beaten semaglutide head-to-head in the SURMOUNT-5 trial. Retatrutide shows the most dramatic weight loss data of all three, but is not yet FDA approved and long-term safety data is still accumulating.
Note: All three are prescription medications. Retatrutide is currently only available through clinical trials.
FAQ
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials through Eli Lilly's TRIUMPH program. FDA approval is expected in 2027 or 2028 based on current trial timelines. Until then, the only legal way to access retatrutide is through enrollment in a clinical trial. Research-grade retatrutide is sold for laboratory research only and is not for human use.
Are GI side effects worse with each newer generation?
Not exactly. The GI side effect pattern (nausea, vomiting, diarrhea) is similar across all three drugs, with most occurring during the dose-titration phase. Some research suggests GIP receptor activation in tirzepatide may actually reduce nausea compared to semaglutide alone. Retatrutide's GI profile is still being characterized in trials but appears similar.
Which has the best safety record?
Semaglutide has 8+ years of post-market safety data (FDA-approved 2017). Tirzepatide has 4+ years (approved 2022). Retatrutide has only clinical trial safety data so far. For patients prioritizing long-term safety evidence, semaglutide has the largest body of real-world data.
How does insurance coverage compare?
Coverage varies dramatically by plan and indication. Many insurers cover semaglutide and tirzepatide for diabetes (Ozempic, Mounjaro) but require prior authorization or deny coverage for obesity (Wegovy, Zepbound). Patients with both diabetes and obesity often have an easier path to coverage. Retatrutide has no commercial pricing yet.
Can I switch between them?
Switching between GLP-1 medications is common and generally safe under physician supervision. Most clinicians recommend a 1–2 week washout when switching to avoid additive side effects, then starting the new drug at its standard low dose for re-titration. Patients should not switch without medical guidance.
Why does retatrutide produce so much more liver fat reduction?
The glucagon receptor (the third receptor only retatrutide targets) directly stimulates fat oxidation in the liver. This is a different mechanism from semaglutide and tirzepatide's appetite-suppression-driven weight loss. The Phase 3 TRIUMPH-4 trial reported up to 86% liver fat reduction — the most dramatic effect on hepatic fat seen in any GLP-1-class drug.
For educational and research purposes only. Not medical advice.
Have a question about Semaglutide vs Tirzepatide vs Retatrutide — GLP-1 Comparison? Send us an email →